1.Effect of Chitosan Oligosaccharide on Enzymes for Cancer Chemoprevention.
To Hun KIM ; Young Jung JO ; Young Min HA ; Yun Hee SHON ; Byung Jo BAE ; Kyung Soo NAM
Journal of the Korean Cancer Association 2001;33(1):64-70
PURPOSE: Two types of chitosan oligosaccharides (COSs), COS I and COS II, were investigated for the effects on ascitic tumor and enzymes for cancer chemoprevention. MATERIALS AND METHODS: Chitosan oligosaccharides were administered once daily for 10 days after the tumor implantation. The change of body weight was observed for 20 days, and the survival rate of mice was determined after 21 days. Chitosan oligosaccharides were administered once daily for 10 days before the tumor implantation (1 106 cells). The number of ascitic tumor cells were measured at 6 days after tumor implantation. Chemopreventive potential of chitosan oligosaccharides was examined by the induction of quinone reductase and inhibition of cytochrome P450 1A1. RESULTS: Chitosan oligosaccharides exerted antitumor activity by inhibiting the growth of Ehrlich ascites tumor cells in vivo. Mice given Ehrlich cells and 10 or 100 mg/kg body weight of chitosan oligosaccharides had 33% survival after 21 days. Quinone reductase activity was increased with chitosan oligosaccharides. There were 26% and 33% inhibition in the activity of cytochrome P450 1A1 enzyme with the treatment of COS I and COS II, respectively. CONCLUSION: These results suggest that chitosan oligosaccharides has antitumor activity and cancer chemo preventive potential by inducing QR activity and inhibiting cytochrome P450 1A1.
Animals
;
Body Weight
;
Carcinoma, Ehrlich Tumor
;
Chemoprevention*
;
Chitosan*
;
Cytochrome P-450 Enzyme System
;
Mice
;
NAD(P)H Dehydrogenase (Quinone)
;
Oligosaccharides
;
Survival Rate
2.Apple AirPods Pro as a Hearing Assistive Device in Patients with Mild to Moderate Hearing Loss
Ga-Young KIM ; Hee Jung YUN ; Mini JO ; Seoyoung JO ; Young Sang CHO ; Il Joon MOON
Yonsei Medical Journal 2024;65(10):596-601
Purpose:
This study aimed to assess the feasibility of the Apple AirPods Pro with the headphone accommodation feature as a hearing assistive device for patients with mild to moderate hearing loss (HL).
Materials and Methods:
The study included a total of 35 participants with mild to moderate HL. To determine the degree of HL in the participants, a screening test using pure-tone audiometry was conducted prior to the main tests of functional gain, word recognition score (WRS), and sentence recognition in noisy environments. The study employed two hearing devices: the Bean (a personal sound amplification product, PSAP) and the AirPods Pro.
Results:
Regarding functional gain, there were no significant differences between the Bean and the AirPods Pro at all frequencies, except 8 kHz. In terms of WRS, both the Bean and the AirPods Pro had higher scores than the unaided condition. In sentence recognition, both the Bean and the AirPods Pro had higher scores than the unaided condition. During real-ear measurement, the Bean demonstrated consistent frequency responses, while the AirPods had a deviation exceeding 10 dB SPL at 6 kHz in the left ear.This deviation was absent for all other frequencies.
Conclusion
This study shows that the Apple AirPods Pro, with its headphone accommodation feature, performed similarly to a validated PSAP and improved hearing compared to unaided conditions.
3.Multifocal Brain Infarction and Intraventricular Hemorrhage in an Infant during Treatment of Diabetic Ketoacidosis.
Kyung Ran SON ; Joon Sung KIM ; Hwa Yun LEE ; Ha Young NOH ; Hee Jo BACK ; Young Jong WOO
Journal of Korean Society of Pediatric Endocrinology 2002;7(2):225-229
Fatal complications including cerebral edema and neurologic collapse occur during treatment of diabetic ketoacidosis(DKA). A 6-week-old female infant with fever, dehydration and drowsy mental status was diagnosed as DKA and neurologically deteriorated during treatment. The cranial computed tomography scan revealed multifocal brain infarctions of the left caudate nucleus, bilateral frontal periventricular white matter, and right parietal cortex. A moderate amount of hemorrhage was also noted in both lateral ventricles. She recovered rapidly with supportive treatment over time. The clinical course and radiologic findings of this patient emphasize the importance of brain infarction as a cause of persistent neurologic loss in children with DKA.
Brain Edema
;
Brain Infarction*
;
Brain*
;
Caudate Nucleus
;
Child
;
Dehydration
;
Diabetic Ketoacidosis*
;
Female
;
Fever
;
Hemorrhage*
;
Humans
;
Infant*
;
Lateral Ventricles
;
Rabeprazole
4.Unilateral Renal Agenesis in 2 Siblings.
Yong Duk YOU ; Kong Jo KIM ; Hee Jo YANG ; Hyun Ki JO ; Doo Sang KIM ; Chang Ho LEE ; Yun Soo JEON ; Nam Kyu LEE
Korean Journal of Urology 2006;47(9):1019-1021
Unilateral renal agenesis associated with genito-urinary disease was found in 2 siblings of a single family. There are a few reports of familial unilateral renal agenesis. Bilateral renal agenesis is a fetal condition and unilateral renal agenesis or hypoplasia is usually asymptomatic, so investigations for renal anomalies have not been frequently undertaken in healthy members of families in which bilateral agenesis has occurred. The present report suggests that unilateral renal agenesis could occur as a manifestation of a genetic disorder.
Humans
;
Kidney Diseases
;
Siblings*
5.Pharmacotherapeutic Problems and Pharmacist Interventions in a Medical Intensive Care Unit.
Tae Yun PARK ; Sang Min LEE ; Sung Eun KIM ; Ka Eun YOO ; Go Wun CHOI ; Yun Hee JO ; Yoonsook CHO ; Hyeon Joo HAHN ; Jinwoo LEE ; A Jeong KIM
Korean Journal of Critical Care Medicine 2015;30(2):82-88
BACKGROUND: Interest in pharmacist participation in the multidisciplinary intensive care team is increasing. However, studies examining pharmacist interventions in the medical intensive care unit (MICU) are limited in Korea. The aim of this study was to describe the current status of pharmacist interventions and to identify common pharmacologic problems requiring pharmacist intervention in the MICU. METHODS: Between September 2013 and August 2014, a retrospective, observational study was conducted in the 22-bed MICU at a university hospital. Data were obtained from two trained pharmacists who participated in MICU rounds three times a week. In addition to patient characteristics, data on the cause, type, related drug, and acceptance rate of interventions were collected. RESULTS: In 340 patients, a total of 1211 pharmacologic interventions were performed. The majority of pharmacologic interventions were suggested by pharmacists at multidisciplinary rounds in the MICU. The most common pharmacologic interventions were adjustment of dosage and administration (n = 328, 26.0%), followed by parenteral/enteral nutritional support (n = 228, 18.1%), the provision of drug information (n = 228, 18.1%), and advice regarding pharmacokinetics (n = 118, 9.3%). Antimicrobial agents (n = 516, 42.6%) were the most frequent type of drug associated with pharmacist interventions. The acceptance rate of interventions was 84.1% with most accepted by physicians within 24 hours (n = 602, 92.8%). CONCLUSIONS: Medication and nutritional problems are frequently encountered pharmacotherapeutic problems in the MICU. Pharmacist interventions play an important role in the management of these problems.
Anti-Infective Agents
;
Humans
;
Critical Care
;
Intensive Care Units*
;
Korea
;
Nutritional Support
;
Observational Study
;
Pharmacists*
;
Pharmacokinetics
;
Retrospective Studies
6.Corrigendum: Infection Control in Parenteral Nutrition Preparation and Compounding
Ji Hyeong CHOE ; Jin Hee BAEK ; Yun Hee JO ; Yoon Sook CHO
Journal of Clinical Nutrition 2019;11(1):29-30
The authors revised some errors regarding Table 5 and 6 in the article as the corrigendum. Because it is not official and may be changed in the revision due out in June 2019, Table 5 and 6 should be deleted and do not refer to it.
7.Infection Control in Parenteral Nutrition Preparation and Compounding.
Ji Hyeong CHOE ; Jin Hee BAEK ; Yun Hee JO ; Yoon Sook CHO
Journal of Clinical Nutrition 2018;10(2):31-37
Recently, in Korea, the importance of preparation and use of injectable drugs has been emphasized due to successive fatal accidents caused by injection infections. Parenteral nutrition (PN) has also been identified as a cause of infection. Cases of infection due to PN have been reported not only in Korea, but also abroad, and contamination occurs mainly during the preparation of PN. Because sterile preparation and compounding of injections are very important for infection control and patient safety, this article reviews the major guidelines outlined thus far. The Korea Ministry of Food and Drug Safety in 2006 published guidelines and the KSHP (Korean Society of Health-System Pharmacists) recently issued guidelines for the aseptic preparation of injections. In addition, as US guidelines, the ASHP (American Society of Health-System Pharmacists) guidelines and United States Pharmacopeia (USP) < 797 > are also reviewed. The recent guidelines published by the KSHP have significance in that they were adopted in accordance with the domestic reality, even though they conform to foreign guidelines, and are expected to be guidelines for hospital pharmacists performing aseptic preparation work. In addition, the Korea Ministry of Health and Welfare is considering appropriate guidelines for the safe management of medications, training staff for infection prevention and strengthening staff capacity. Furthermore, the gradual expansion of aseptic compounding facilities and human resources, as well as the provision of adequate medical costs are also considered. Based on the establishment and standardization of injectable drugs compounding guidelines for Korean hospitals, it is believed that if human resources and facilities are supported and medical charges are improved, it will be possible to expect the safer preparation and use of injections.
Drug Compounding
;
Humans
;
Infection Control*
;
Korea
;
Parenteral Nutrition*
;
Patient Safety
;
Pharmacists
;
United States
8.Mullerian inhibiting substance as a predictive marker of menopausal transition.
Ji Sun WE ; Jae Yen SONG ; Sue Yeon KIM ; Yun Sung JO ; Hyun Hee JO ; Mee Ran KIM ; Jin Hong KIM ; Jang Heub KIM
Korean Journal of Obstetrics and Gynecology 2007;50(10):1396-1404
OBJECTIVE: To identified whether serum Mullerian inhibiting substance (MIS) level may be used as a predictive marker of menopausal transition. METHODS: Serum MIS level was measured in reproductive women (n=87), in menopausal transition women (n=58), and in menopausal women (n=5) by ELISA. And we examined the immunohistochemical staining of the MIS in the ovarian tissues of 15 reproductive, 15 menopausal transition, and 5 menopausal women. RESULTS: 1. In the reproductive women, mean serum MIS level was 1.73+/-1.07 ng/ml. In the menopausal transition women, mean serum MIS level was 0.18+/-0.11 ng/ml. Serum MIS level did not show any significant fluctuation patterns according to follicular development. In menopausal transition women, serum MIS level was significantly lower than that of reproductive women (P<0.001). The cutoff value of serum MIS level for menopausal transition was 0.5 ng/mg. In the menopausal women, serum MIS level was not detected. 2. Serum MIS level was significantly decreased as patient age was increased. 3. In the reproductive group, the immunohistochemical staining demonstrated strong expression of MIS in the granulosa cells of the primary follicles and the growing follicles, but not in corpus luteum, preovulatory mature follicle, atretic follicle, and corpus luteum. In the menopausal transition women, immunohistochemical staining for MIS was observed in the nearly same pattern as that of thereproductive women, but with weaker expression. In the menopausal women, immunohistochemical staining of the MIS was not observed. CONCLUSION: MIS is a good candidate for predictive marker for ovarian aging and perimenopausal transition.
Aging
;
Anti-Mullerian Hormone*
;
Corpus Luteum
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
Granulosa Cells
;
Humans
;
Ovarian Follicle
9.Inflammatory Cytokines and Cognition in Alzheimer’s Disease and Its Prodrome
Su Jeong SEONG ; Ki Woong KIM ; Joo Yun SONG ; Kee Jeong PARK ; Young Tak JO ; Jae Hyun HAN ; Ka Hee YOO ; Hyun Jun JO ; Jae Yeon HWANG
Psychiatry Investigation 2024;21(10):1054-1064
Objective:
The aim of this study was to investigate the association between blood levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) and cognitive impairments among elderly individuals.
Methods:
Peripheral concentration of TNF-α and IL-6 were measured in all subjects. To assess individual cognitive function, the Consortium to Establish a Registry for Alzheimer’s Disease Neuropsychological Assessment Battery (CERAD-NP) was used, and standardized scores (z-scores) were calculated for each test. Cytokine levels were compared between the diagnostic groups, and correlations between blood inflammatory factor levels and z-scores were analyzed.
Results:
The 37 participants included 8 patients with Alzheimer’s disease (AD), 15 subjects with mild cognitive impairment (MCI), and 14 cognitively healthy controls. TNF-α and IL-6 levels were higher in patients with AD than in healthy controls. TNF-α levels were higher in the AD group than in the MCI group. However, after adjusting for age, the associations between diagnosis and TNF-α and IL-6 were not significant. The higher the plasma IL-6 level, the lower the z-scores on the Boston Naming Test, Word List Learning, Word List Recognition, and Constructional Recall. The higher the serum TNF-α level, the lower the z-scores on the Word List Learning and Constructional Recall. Negative correlation between serum TNF-α level and the z-score on Word List Learning remained significant when age was adjusted.
Conclusion
The difference in the blood levels of TNF-α and IL-6 between the diagnostic groups may be associated with aging. However, elevated TNF-α levels were associated with worse immediate memory performance, even after adjusting for age.
10.Real-world Treatment Pattern and Outcomes of Hypercalcemia among Solid Tumor Patients
Da Eun SHIN ; Seol Hee PARK ; Sung Hwan KIM ; Sung Yun SUH ; Yun Hee JO ; Yoon Sook CHO ; Seock Ah IM ; Ju Yeun LEE
Korean Journal of Clinical Pharmacy 2019;29(3):166-172
BACKGROUND: Hypercalcemia is an important metabolic emergency condition in cancer patients. Bisphosphonate is the treatment of choice for hypercalcemia, whereas calcitonin and hydration with furosemide are recommended for acute supportive therapy. However, data regarding real-world treatment patterns and outcomes of pharmacological treatments are limited. Therefore, we aimed to investigate the treatment patterns and clinical outcomes of hypercalcemia treatment in solid tumor patients. METHODS: Electronic medical records of 123 adults with solid cancers and albumin-corrected calcium levels >10.5 mg/dL or ionized calcium levels >1.35 mmol/L were reviewed. We retrospectively analyzed the pharmacological treatment and recovery rate according to the severity of hypercalcemia. RESULTS: A total of 177 cases were identified, of which 49 were not treated and 30 were treated with hydration only. In moderate-to-severe cases, 86.5% received pharmacological treatment. Thirty-four cases (19.2%) were treated with bisphosphonate alone and 58 cases (32.8%) were treated with bisphosphonate and calcitonin. In mild hypercalcemia cases, the recovery rate was higher for those receiving hydration only or pharmacological treatment (79.7%) than for those receiving no treatment (61.4%, p = 0.041). Most moderate-to-severe cases were treated with medication and of those treated, 56.3% recovered. The recovery rate was lower in those treated with bisphosphonate alone (38.2%) than in those who underwent calcitonin combination treatment (73.7%, p = 0.001). CONCLUSIONS: Bisphosphonate combined with calcitonin was found to be more effective than bisphosphonate alone for the treatment of moderate-to-severe hypercalcemia. Considering the current shortage of calcitonin, further efforts are required to ensure its stable supply.
Adult
;
Calcitonin
;
Calcium
;
Electronic Health Records
;
Emergencies
;
Furosemide
;
Humans
;
Hypercalcemia
;
Retrospective Studies